Microsoft to Acquire Rosetta Biosoftware from Merck
Microsoft has signed an agreement to acquire Rosetta Biosoftware , a unit of Rosetta Inpharmatics, from parent company Merck for undisclosed consideration. Microsoft said that the deal will enable it to add genetic, genomic , metabolomic , and proteomic data management software into its own Amalga Life Sciences platform for "enhanced translational research capabilities." Merck will become a customer of the Amalga Life Sciences 2009 platform and provide "strategic input" to Microsoft on the evolution of new solutions that incorporate Rosetta Biosoftware technologies, Microsoft said. The Redmond, Wash.-based software giant launched the Amalga Life Sciences 2009 platform in April. "The newly combined offering will enable customers to improve the management and analysis of genomic, biological and research data , helping to bring lifesaving drugs and therapies to market faster and accelerate the realization of personalized medicine," Peter Neupert, corpora...